Drug Trial Radar · NCT06765109
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
Jul 17, 2025
Primary completion
Dec 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- Nuvalent Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma Kinase (ALK) positive, advanced Non-Small Cell Lung Cancer (NSCLC).
Conditions
- Non-small Cell Lung Cancer
- Anaplastic Lymphoma Kinase-positive
Interventions
Neladalkib (NVL-655)Drug
Oral tablet of Neladalkib (NVL-655)
AlectinibDrug
Oral capsule of alectinib
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) per blinded independent central review (BICR)Time frame: Up to 5 years after first patient dosed
Locations
159 sites in 29 countries. Site status is shown where the registry gives one.
Palo Verde Hematology Oncology
Glendale, Arizona · Recruiting
Hoag Hospital Newport Beach
Newport Beach, California · Recruiting
University of California, Irvine Health
Orange, California · Recruiting
Rocky Mountain Cancer Centers
Boulder, Colorado · Recruiting
Sylvester Comprehensive Cancer Center Miami
Miami, Florida · Recruiting
AdventHealth Cancer Institute
Orlando, Florida · Recruiting
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida · Recruiting
Winship Cancer Institute of Emory University
Atlanta, Georgia · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan · Withdrawn
Washington University Center for Advanced Medicine
St Louis, Missouri · Recruiting
NYU Langone's Perlmutter Cancer Center
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Optum Medical Care, PC
Westbury, New York · Recruiting
Carolinas Medical Center
Charlotte, North Carolina · Recruiting
Duke Cancer Center
Durham, North Carolina · Recruiting
University of Cincinnati Cancer Center
Cincinnati, Ohio · Recruiting
The Ohio State University
Columbus, Ohio · Recruiting
Alliance Cancer Specialists
Sellersville, Pennsylvania · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Recruiting
University of Washington - Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Compass Oncology
Vancouver, Washington · Recruiting
Sanatorio Allende
Córdoba, Argentina · Recruiting
Centro Médico Privado CEMIC
Córdoba, Argentina · Recruiting
Sanatorio Parque S.A.
Rosario, Santa Fe Province, Argentina · Recruiting
Peter MacCallum Cancer Centre
Melbourne, Australia · Recruiting
Westmead Hospital
Westmead, New South Wales, Australia · Recruiting
Austin Health
Heidelberg, Victoria, Australia · Recruiting
Wiener Gesundheitsverbund
Vienna, Austria · Recruiting
Cliniques Universitaires Saint-Luc
Brussels, Belgium · Recruiting
Antwerp University Hospital
Edegem, Belgium · Recruiting
UZ Leuven
Leuven, Belgium · Recruiting
Fundação Pio XII
Barretos, Brazil · Recruiting
Santa Casa de Misericordia de Belo Horizonte
Belo Horizonte, Brazil · Recruiting
Irmandade Da Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Brazil · Recruiting
Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul
Porto Alegre, Brazil · Recruiting
Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base
São José do Rio Preto, Brazil · Recruiting
Instituto do Cancer do Estado de São Paulo ICESP
São Paulo, Brazil · Recruiting
A.C.Camargo Cancer Center
São Paulo, Brazil · Recruiting
Showing 40 of 159 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.